Hironobu Hamada Selected Research

Plasminogen Activators (Plasminogen Activator)

1/2019	Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
10/2018	Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis.
1/2016	Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts.
1/2016	Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hironobu Hamada Research Topics

Disease

25	Neoplasms (Cancer) 07/2022 - 11/2004
18	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 02/2002
16	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 08/2007
15	Lung Neoplasms (Lung Cancer) 07/2022 - 10/2008
9	Adenocarcinoma of Lung 01/2022 - 06/2007
9	Malignant Mesothelioma 01/2018 - 03/2006
8	Fibrosis (Cirrhosis) 01/2021 - 01/2017
8	Idiopathic Pulmonary Fibrosis 01/2021 - 02/2002
7	Lung Injury 01/2022 - 12/2002
6	Asthma (Bronchial Asthma) 12/2022 - 03/2006
6	Pneumonia (Pneumonitis) 10/2022 - 11/2004
6	Bronchiectasis 02/2021 - 04/2013
6	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2021 - 01/2016
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 02/2002
5	Inflammation (Inflammations) 01/2021 - 01/2017
5	Neoplasm Metastasis (Metastasis) 09/2020 - 02/2002
4	Disease Progression 07/2022 - 06/2010
4	Acute Lung Injury 01/2022 - 01/2013
3	Respiratory Insufficiency (Respiratory Failure) 02/2022 - 01/2007
3	Emphysema 04/2021 - 01/2016
3	Extrinsic Allergic Alveolitis (Hypersensitivity Pneumonitis) 01/2019 - 12/2002
3	Pleural Effusion (Pleural Effusions) 08/2012 - 03/2006
2	Venous Thromboembolism 02/2021 - 03/2019
2	Disseminated Intravascular Coagulation 02/2021 - 01/2014
2	Dyspnea (Shortness of Breath) 02/2021 - 01/2013
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 12/2018
2	Intracranial Embolism 01/2020 - 03/2019
2	Adenocarcinoma 01/2019 - 06/2007
2	Sepsis (Septicemia) 01/2018 - 01/2013
2	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 06/2017 - 02/2002
2	Bacterial Pneumonia 01/2016 - 02/2002
2	Mesothelioma 02/2013 - 04/2010
1	Exophthalmos (Proptosis) 12/2022
1	Immunoglobulin G4-Related Disease 12/2022
1	Meningoencephalitis 10/2022
1	Chickenpox 10/2022
1	Rheumatoid Arthritis 10/2022
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 04/2022

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 01/2021 - 02/2002
8	LigandsIBA 07/2022 - 01/2016
6	Cisplatin (Platino)FDA LinkGeneric 02/2021 - 03/2006
6	Pharmaceutical PreparationsIBA 02/2021 - 11/2004
5	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2008
5	Bleomycin (Blenoxane)FDA LinkGeneric 01/2021 - 01/2016
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2002
4	CytokinesIBA 01/2021 - 01/2017
4	AntibodiesIBA 11/2019 - 06/2007
4	Mucin-1 (CA 15-3 Antigen)IBA 01/2019 - 03/2006
4	Plasminogen Activator Inhibitor 1IBA 01/2019 - 01/2016
4	Plasminogen Activators (Plasminogen Activator)IBA 01/2019 - 01/2016
4	AsbestosIBA 02/2013 - 03/2006
3	Immunoglobulin G (IgG)IBA 12/2022 - 01/2012
3	SteroidsIBA 12/2022 - 08/2003
3	Receptor for Advanced Glycation End ProductsIBA 01/2022 - 01/2017
3	HMGB1 Protein (HMG1)IBA 12/2021 - 01/2020
3	AntigensIBA 04/2021 - 01/2017
3	pembrolizumabIBA 03/2020 - 03/2019
3	Monoclonal AntibodiesIBA 01/2012 - 07/2004
2	Prednisolone (Predate)FDA LinkGeneric 12/2022 - 01/2018
2	Indicators and Reagents (Reagents)IBA 02/2021 - 01/2007
2	Messenger RNA (mRNA)IBA 01/2021 - 01/2021
2	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2021 - 04/2013
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2017
2	Bronchodilator Agents (Bronchodilators)IBA 01/2021 - 03/2006
2	Small Interfering RNA (siRNA)IBA 01/2021 - 09/2018
2	Immune Checkpoint InhibitorsIBA 11/2020 - 09/2019
2	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 01/2019 - 12/2018
2	suplatast tosilateIBA 01/2019 - 01/2017
2	ChemokinesIBA 01/2019 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2018 - 03/2006
2	Docetaxel (Taxotere)FDA Link 09/2018 - 08/2007
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2017 - 02/2013
2	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2016 - 02/2002
2	SK-216IBA 01/2016 - 01/2016
2	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2014 - 01/2013
2	SugarsIBA 01/2012 - 07/2004
2	Tyrosine Kinase InhibitorsIBA 07/2011 - 06/2008
2	Tumor Biomarkers (Tumor Markers)IBA 10/2008 - 06/2008
2	Glycoproteins (Glycoprotein)IBA 06/2007 - 03/2006
1	GlucocorticoidsIBA 12/2022
1	dupilumabIBA 12/2022
1	InterleukinsIBA 12/2022
1	Interleukin-13IBA 12/2022
1	Methotrexate (Mexate)FDA LinkGeneric 10/2022
1	iguratimodIBA 10/2022
1	Valacyclovir (Valtrex)FDA LinkGeneric 10/2022
1	tepotinibIBA 06/2022
1	capmatinibIBA 06/2022
1	ParaffinIBA 04/2022
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 04/2022

Therapy/Procedure

21	Drug Therapy (Chemotherapy) 07/2022 - 02/2002
9	Therapeutics 01/2021 - 01/2004
6	Radiotherapy 01/2021 - 02/2002
5	Traction 02/2021 - 01/2018
3	Chemoradiotherapy 09/2021 - 10/2017
2	Oral Administration 10/2022 - 06/2017
2	Catheters 01/2020 - 01/2018
2	Aftercare (After-Treatment) 06/2011 - 02/2005
1	Operative Surgical Procedures 07/2022
1	General Anesthesia 02/2022